Would screening for lung cancer benefit 75- to 84-year-old residents of the United States?

abstract：:During tumor development, the spleen acts as an extra-medullar reservoir of LY6Chi inflammatory monocytes, which can migrate toward tumor to differentiate into tumor-associated macrophage (TAMs), renewing the TAM population. In the tumor microenvironment, pro-inflammatory macrophages (M1) acquire anti-inflammatory and...

journal_title：Frontiers in oncology

authors： de-Brito NM,da-Costa HC,Simões RL,Barja-Fidalgo C

更新日期：2019-06-19 00:00:00

abstract：:Esophageal adenocarcinoma (EAC) is a lethal cancer requiring improved screening strategies and treatment options due to poor detection methods, aggressive progression, and therapeutic resistance. Emerging circulating tumor DNA (ctDNA) technologies may offer a unique non-invasive strategy to better characterize the hig...

journal_title：Frontiers in oncology

authors： Kosovec JE,Zaidi AH,Pounardjian TS,Jobe BA

更新日期：2018-12-11 00:00:00

abstract：:Immune checkpoint inhibitors have now become a standard therapy for malignant melanoma. However, as immunotherapies are effective in only a limited number of patients, biomarker development remains one of the most important clinical challenges. Biomarkers predicting clinical benefit facilitate appropriate selection of...

journal_title：Frontiers in oncology

authors： Kitano S,Nakayama T,Yamashita M

更新日期：2018-07-18 00:00:00

abstract：:Although colorectal cancer is a preventable and curable disease if early stage tumors are removed, it still represents the second cause of cancer-related death worldwide. Surgical resection is the only curative treatment but once operated the patient is either subjected to adjuvant chemotherapy or not, depending on th...

journal_title：Frontiers in oncology

authors： Mihalache A,Delplanque JF,Ringot-Destrez B,Wavelet C,Gosset P,Nunes B,Groux-Degroote S,Léonard R,Robbe-Masselot C

更新日期：2015-10-08 00:00:00

abstract：:Many similar characteristics in human and dog cancers including, spontaneous development, clinical presentation, tumor heterogeneity, disease progression, and response to standard therapies have promoted the approval of this comparative model as an alternative to mice. Breast cancer represents the second most frequent...

journal_title：Frontiers in oncology

authors： Amirkhani Namagerdi A,d'Angelo D,Ciani F,Iannuzzi CA,Napolitano F,Avallone L,De Laurentiis M,Giordano A

更新日期：2020-11-12 00:00:00

abstract：:Tumor-induced angiogenesis has been a significant focus of anti-cancer therapies for several decades. The immature and "leaky" tumor vasculature leads to significant cancer cell intravasation, increasing the metastatic potential, while the disoriented and hypo-perfused tumor vessels hamper the anti-tumor efficacy of i...

journal_title：Frontiers in oncology

authors： Mattheolabakis G,Mikelis CM

更新日期：2019-11-12 00:00:00

abstract：:Epstein-Barr virus (EBV) establishes lifelong latent infection in humans and is associated with several lymphoid and epithelial cancers. In nasopharyngeal carcinoma (NPC), EBV expresses few viral proteins but elevated levels of Bam-HI A rightward transcripts (BARTs) RNA, which includes viral microRNAs and long non-cod...

journal_title：Frontiers in oncology

authors： Verhoeven RJA,Tong S,Mok BW,Liu J,He S,Zong J,Chen Y,Tsao SW,Lung ML,Chen H

更新日期：2019-10-22 00:00:00

abstract：:The National Cancer Institute (NCI) clinical cooperative groups have been instrumental over the past 50 years in developing clinical trials and evidence-based clinical trial processes for improvements in patient care. The cooperative groups are undergoing a transformation process to launch, conduct, and publish clinic...

journal_title：Frontiers in oncology

authors： Followill DS,Urie M,Galvin JM,Ulin K,Xiao Y,Fitzgerald TJ

更新日期：2012-12-26 00:00:00

abstract：:Background: Stabilized mutant p53 protein (mutp53) is a novel target in epithelial ovarian cancer. Due to aberrant conformation, mutp53 proteins depend on folding support by the Hsp90 chaperone. Hsp90 blockade induces degradation of mutp53, resulting in tumor cell cytotoxicity and increased sensitivity to chemotherape...

journal_title：Frontiers in oncology

authors： Ray-Coquard I,Braicu I,Berger R,Mahner S,Sehouli J,Pujade-Lauraine E,Cassier PA,Moll UM,Ulmer H,Leunen K,Zeimet AG,Marth C,Vergote I,Concin N

更新日期：2019-09-10 00:00:00

abstract：:Approximately 20% of unselected cases and 30% cytogenetically diploid cases of acute myeloid leukemia (AML) and 80% of grade II-III gliomas and secondary glioblastomas carry mutations in the isocitrate dehydrogenase (IDH) 1 and 2 genes. IDH1/2 mutations prevent oxidative decarboxylation of isocitrate to α-ketoglutarat...

journal_title：Frontiers in oncology

authors： Rakheja D,Medeiros LJ,Bevan S,Chen W

更新日期：2013-07-02 00:00:00

abstract：:Objective: Changes in the number of various tumor-infiltrating lymphocytes (TILs) and degrees of vascular normalization in breast cancer (BC) patients after neoadjuvant chemotherapy (NAC) were analyzed to screen key factors that can predict the prognosis. Methods: HE-stained sections were used to assess the degree of ...

journal_title：Frontiers in oncology

authors： Wang Q,Xiang Q,Yu L,Hu T,Chen Y,Wang J,Nie X,Cheng J

更新日期：2020-01-22 00:00:00

abstract：:Objective: The objective of this study was to summarize the clinicopathological characteristics of the CLDN18-ARHGAP fusion gene in gastric cancer patients. Background: The CLDN18-ARHGAP26 fusion gene is one of the most frequent somatic genomic rearrangements in gastric cancer, especially in the genomically stable (GS...

journal_title：Frontiers in oncology

authors： Zhang WH,Zhang SY,Hou QQ,Qin Y,Chen XZ,Zhou ZG,Shu Y,Xu H,Hu JK

更新日期：2020-09-02 00:00:00

abstract：Introduction:Colorectal cancer (CRC) is the second leading cause of cancer death worldwide and most deaths result from metastases. We have analyzed animal models in which Apc, a gene that is frequently mutated during the early stages of colorectal carcinogenesis, was inactivated and human samples to try to identify nov...

journal_title：Frontiers in oncology

authors： Queiroz CJS,Song F,Reed KR,Al-Khafaji N,Clarke AR,Vimalachandran D,Miyajima F,Pritchard DM,Jenkins JR

更新日期：2020-08-11 00:00:00

abstract：:Retroviruses that have the ability to infect germ line cells can become an integral and inherited part of the host genome. About 8% of the human chromosomal DNA consists of sequences derived from infections by retroviruses that presumably circulated 2-40 millions of years ago, and some elements are actually much older...

journal_title：Frontiers in oncology

authors： Hohn O,Hanke K,Bannert N

更新日期：2013-09-20 00:00:00

abstract：:Background: Pediatric neurofibromatosis type 1 (NF1) patients rarely develop aggressive central nervous system tumors. Among high-grade gliomas (HGGs), histone mutant diffuse midline gliomas (DMGs H3 K27M-mutant) have exceptionally been reported. The aim of this retrospectives single-center study was to compare the cl...

journal_title：Frontiers in oncology

authors： Garibotto F,Madia F,Milanaccio C,Verrico A,Piccardo A,Tortora D,Piatelli G,Diana MC,Capra V,Garrè ML,Rossi A,Morana G

更新日期：2020-06-03 00:00:00

abstract：:The treatment of melanoma by targeted inhibition of the mutated kinase BRAF with small molecules only temporarily suppresses metastatic disease. In the face of chemical inhibition tumor plasticity, both innate and adaptive, promotes survival through the biochemical and genetic reconfiguration of cellular pathways that...

journal_title：Frontiers in oncology

authors： Parker R,Vella LJ,Xavier D,Amirkhani A,Parker J,Cebon J,Molloy MP

更新日期：2015-05-15 00:00:00

abstract：:Over the last decade, based on the extensive development of preclinical animal studies and clinical trials, the efficacy, and mechanisms of immunotherapy have been fully explored. Significant and lasting clinical responses with immunotherapy provide a new breakthrough treatment for a variety of refractory cancer histo...

journal_title：Frontiers in oncology

authors： Bai R,Chen N,Li L,Du N,Bai L,Lv Z,Tian H,Cui J

更新日期：2020-08-06 00:00:00

abstract：PURPOSE/OBJECTIVES:Stereotactic body radiation therapy (SBRT) is emerging as a minimally invasive alternative to brachytherapy to deliver highly conformal, dose--escalated radiation therapy (RT) to the prostate. SBRT alone may not adequately cover the tumor extensions outside the prostate commonly seen in unfavorable p...

journal_title：Frontiers in oncology

authors： Mercado C,Kress MA,Cyr RA,Chen LN,Yung TM,Bullock EG,Lei S,Collins BT,Satinsky AN,Harter KW,Suy S,Dritschilo A,Lynch JH,Collins SP

更新日期：2016-05-06 00:00:00

abstract：BACKGROUND:Radiation exposure can lead to detrimental effects in skin microcirculation. The precise relationship between radiation dose received and its effect on cutaneous perfusion still remains controversial. Previously, we have shown that hyperspectral imaging (HSI) is able to demonstrate long-term reductions in cu...

journal_title：Frontiers in oncology

authors： Chin MS,Freniere BB,Lancerotto L,Lujan-Hernandez J,Saleeby JH,Lo YC,Orgill DP,Lalikos JF,Fitzgerald TJ

更新日期：2015-10-26 00:00:00

abstract：Background:The receptor tyrosine kinase mesenchymal-epithelial transition factor (MET) is frequently altered in cancers and is a common therapeutic target for cancers with MET variants. However, abnormal MET alterations and their associations with patient outcome across different cancer types have not been studied simu...

journal_title：Frontiers in oncology

authors： Li J,Hu K,Zhou L,Huang J,Zeng S,Xu Z,Yan Y

更新日期：2020-10-15 00:00:00

abstract：BACKGROUND:Whole-brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), or both are commonly employed in the treatment of limited brain metastases in the initial or recurrent setting. Hypofractionated partial volume irradiation is also employed, however, published experience using helical TomoTherapy (HT) for...

journal_title：Frontiers in oncology

authors： Elson A,Walker A,Bovi JA,Schultz C

更新日期：2015-02-09 00:00:00

abstract：:P62 and ubiquitin are small regulatory proteins demonstrated to have implications in the prognosis and survival of various malignancies including: hepatocellular, breast, ovarian, and some gastrointestinal carcinomas. Several trials studied the link of their activity to the extrinsic apoptosis pathway and showed that ...

journal_title：Frontiers in oncology

authors： Mohamed A,Ayman A,Deniece J,Wang T,Kovach C,Siddiqui MT,Cohen C

更新日期：2015-03-30 00:00:00

abstract：:Mechanisms of dysfunctional T cell immunity in Hepatocellular Carcinoma (HCC) need to be well defined. B7 family molecules provide both co-stimulatory and co-inhibitory signals to T cells while tryptophan degrading enzymes like Indoleamine 2,3 dioxygenase (IDO) and Tryptophan 2,3 Dioxygenase (TDO) mediate tumor immune...

journal_title：Frontiers in oncology

authors： Chinnadurai R,Scandolara R,Alese OB,Arafat D,Ravindranathan D,Farris AB,El-Rayes BF,Gibson G

更新日期：2020-09-03 00:00:00

abstract：:Epithelial ovarian cancer (EOC) is the most malignant gynecological carcinoma and is of a high incidence of death due to detection at late stages when metastasis already occurs. However, the mechanism underlying metastasis of EOC remains unclear. Analysis of the open database and experiments with immunochemistry showe...

journal_title：Frontiers in oncology

authors： Zhao C,She X,Zhang Y,Liu C,Li P,Chen S,Sai B,Li Y,Feng J,Liu J,Sun Y,Xiao S,Li L,Wu M

更新日期：2020-02-14 00:00:00

abstract：:Glycosylation is one of the key components influencing several signaling pathways implicated in cell survival and growth. The Notch signaling pathway plays a pivotal role in numerous cell fate specifications during metazoan development. Both Notch and its ligands are repeatedly glycosylated by the addition of sugar mo...

journal_title：Frontiers in oncology

authors： Pakkiriswami S,Couto A,Nagarajan U,Georgiou M

更新日期：2016-02-18 00:00:00

abstract：:Breast cancer is the most common cancer in women worldwide. Elucidation of underlying biology and molecular pathways is necessary for improving therapeutic options and clinical outcomes. CLN3 protein (CLN3p), deficient in neurodegenerative CLN3 disease is anti-apoptotic, and defects in the CLN3 gene cause accelerated ...

journal_title：Frontiers in oncology

authors： Makoukji J,Raad M,Genadry K,El-Sitt S,Makhoul NJ,Saad Aldin E,Nohra E,Jabbour M,Sangaralingam A,Chelala C,Habib RH,Boulos F,Tfayli A,Boustany RM

更新日期：2015-10-12 00:00:00

abstract：:The clinical benefit of a multidisciplinary clinic practice model has been well described in a variety of medical specialties and cancer types. It proves particularly valuable when an integrated team is needed to optimally manage patients with rare or complex neoplasms. However, the ideal implementation of an integrat...

journal_title：Frontiers in oncology

authors： Tyler KH,Haverkos BM,Hastings J,Hu E,Philips R,Gru AA,Welliver MX,Mishra A,Wong HK,Porcu P

更新日期：2015-06-17 00:00:00

abstract：:AUNIP, a novel prognostic biomarker, has been shown to be associated with stromal and immune scores in oral squamous cell carcinoma (OSCC). Nonetheless, its role in other cancer types was unclear. In this study, AUNIP expression was increased in hepatocellular carcinoma (HCC) and lung adenocarcinoma (LUAD) according t...

journal_title：Frontiers in oncology

authors： Ma C,Kang W,Yu L,Yang Z,Ding T

更新日期：2020-12-09 00:00:00

abstract：:In the thorax, the extent of tumor may be more accurately defined with the addition of (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) to computed tomography (CT). This led to the increased utility of FDG-PET or PET/CT in the treatment planning of radiotherapy for non-small cell lung cancer (NSCLC). ...

journal_title：Frontiers in oncology

authors： Chi A,Nguyen NP

更新日期：2014-10-07 00:00:00

abstract：:Metastasis remains the cause of over 90% of cancer-related deaths. Cells undergoing metastasis use phenotypic plasticity to adapt to their changing environmental conditions and avoid therapy and immune response. Reversible transitions between epithelial and mesenchymal phenotypes - epithelial-mesenchymal transition (E...

journal_title：Frontiers in oncology

authors： Subbalakshmi AR,Kundnani D,Biswas K,Ghosh A,Hanash SM,Tripathi SC,Jolly MK

更新日期：2020-09-08 00:00:00